share_log

Evolent Health (NYSE:EVH) Pulls Back 5.1% This Week, but Still Delivers Shareholders Incredible 33% CAGR Over 5 Years

Evolent Health (NYSE:EVH) Pulls Back 5.1% This Week, but Still Delivers Shareholders Incredible 33% CAGR Over 5 Years

evolent health(紐交所:EVH)本週回落5.1%,但仍以驚人的33%年均複合增長率回報股東5年
Simply Wall St ·  09/06 10:32

We think all investors should try to buy and hold high quality multi-year winners. And we've seen some truly amazing gains over the years. To wit, the Evolent Health, Inc. (NYSE:EVH) share price has soared 313% over five years. And this is just one example of the epic gains achieved by some long term investors. And in the last month, the share price has gained 49%.

我們認爲,所有投資者都應該嘗試買入並持有高質量的多年期贏家。這些年來,我們已經看到了一些非常驚人的成果。換句話說,Evolent Health, Inc.(紐約證券交易所代碼:EVH)的股價在五年內飆升了313%。這只是一些長期投資者取得巨大收益的一個例子。而在上個月,股價上漲了49%。

While the stock has fallen 5.1% this week, it's worth focusing on the longer term and seeing if the stocks historical returns have been driven by the underlying fundamentals.

儘管該股本週下跌了5.1%,但值得關注長期來看,看看股票的歷史回報是否是由基礎基本面推動的。

Given that Evolent Health didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. When a company doesn't make profits, we'd generally hope to see good revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one would hope for good top-line growth to make up for the lack of earnings.

鑑於Evolent Health在過去十二個月中沒有盈利,我們將專注於收入增長,以快速了解其業務發展。當一家公司沒有盈利時,我們通常希望看到良好的收入增長。一些公司願意推遲盈利以更快地增加收入,但在這種情況下,人們希望良好的收入增長來彌補收益不足。

For the last half decade, Evolent Health can boast revenue growth at a rate of 24% per year. That's well above most pre-profit companies. Arguably, this is well and truly reflected in the strong share price gain of 33%(per year) over the same period. It's never too late to start following a top notch stock like Evolent Health, since some long term winners go on winning for decades. On the face of it, this looks lke a good opportunity, although we note sentiment seems very positive already.

在過去的五年中,Evolent Health可以實現每年24%的收入增長。這遠高於大多數盈利前公司。可以說,這真實地反映在同期股價強勁上漲33%(每年)上。現在開始關注像Evolent Health這樣的一流股票永遠不會太晚,因爲一些長期贏家已經贏了幾十年。從表面上看,這似乎是一個很好的機會,儘管我們注意到市場情緒似乎已經非常樂觀了。

The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail).

下圖顯示了收入和收入隨時間推移的跟蹤情況(如果您點擊圖片,可以看到更多細節)。

big
NYSE:EVH Earnings and Revenue Growth September 6th 2024
紐約證券交易所:EVH 收益和收入增長 2024 年 9 月 6 日

Evolent Health is well known by investors, and plenty of clever analysts have tried to predict the future profit levels. So we recommend checking out this free report showing consensus forecasts

Evolent Health爲投資者所熟知,許多聰明的分析師都試圖預測未來的利潤水平。因此,我們建議您查看這份顯示共識預測的免費報告

A Different Perspective

不同的視角

Evolent Health shareholders are up 19% for the year. But that return falls short of the market. If we look back over five years, the returns are even better, coming in at 33% per year for five years. Maybe the share price is just taking a breather while the business executes on its growth strategy. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Consider for instance, the ever-present spectre of investment risk. We've identified 2 warning signs with Evolent Health , and understanding them should be part of your investment process.

Evolent Health的股東今年上漲了19%。但是這種回報不及市場。如果我們回顧五年,回報率甚至更高,五年內每年回報率爲33%。也許在企業執行增長戰略的同時,股價只是在稍作休息。我發現將長期股價視爲業務績效的代表非常有趣。但是,要真正獲得見解,我們還需要考慮其他信息。例如,投資風險的幽靈無處不在。我們已經確定了Evolent Health的兩個警告信號,了解它們應該是您投資過程的一部分。

If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: many of them are unnoticed AND have attractive valuation).

如果你想和管理層一起購買股票,那麼你可能會喜歡這份免費的公司清單。(提示:其中許多未被注意且估值誘人)。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

請注意,本文引用的市場回報反映了目前在美國交易所交易的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接聯繫我們。或者,也可以發送電子郵件至編輯團隊 (at) simplywallst.com。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論